Document Type : Original Article

Authors

1 Department of Radio-oncology, Medical School of Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Neurosurgery, Medical school of Shiraz University of Medical Sciences, Shiraz, Iran

3 Hepatitis Research Center, Nursing and Midwifery Faculty, Lorestan University of Medical Sciences, Khorramabad, Iran

Abstract

Background: Cognitive impairment is one of the common problems in patients undergoing radiotherapy, but there is no way to prevent it until this time. The aim of this study was to determine the effect of memantine on the prevention of cognitive impairment in patients with brain tumour undergoing radiotherapy.
Method: In this clinical trial study, 70 patients under radiotherapy were selected and randomly divided into two groups. The first group received 10 mg of memantine tablets daily for six month and the second group received placebo at the same dose and time. Cognitive impairment was evaluated through Mini-Mental Status Examination questionnaire and compared between the two groups.
Results: The mean score of cognitive impairment before and after radiotherapy in the control and intervention groups were 27.97 ± 1.52 and 27.66 ± 1.35 (P = 0.26), in the following month were 27.74 ± 1.74 and 27.63 ± 1.35 (P = 0.73), in the following three months were 23.17 ± 1.81 and 24.77 ± 1.44 (P <0.001), and in the following six months were 20.66 ± 1.8 and 23.17 ± 1.42 (P < 0.001). In addition, changes in cognitive impairment score were significantly different between the two groups (P < 0.001).
Conclusion: It seems that memantine is effective in preventing the cognitive impairment in patients undergoing radiotherapy following brain tumour surgery and the implementation of this referee can be associated with improved cognitive function over time.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2022.90186.1567

  1. Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348-54. doi: 10.1016/j.ijrobp.2012.11.031.
  2. Ohrn KE, Wahlin YB, Sjödén PO. Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer. 2001;9(4):247-57. doi: 10.1007/s005200000214.
  3. Hancock PJ, Epstein JB, Sadler GR. Oral and dental management related to radiation therapy for head and neck cancer. J Can Dent Assoc. 2003;69(9):585-90.
  1. Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415-20. doi: 10.1200/JCO.2005.03.3001.
  2. Taylor R, O'Carroll R. Cognitive estimation in neurological disorders. Br J Clin Psychol. 1995;34(2):223-8. doi: 10.1111/j.2044-8260.1995.tb01456.x.
  3. Leszczynski K, Boyko S. On the controversies surrounding the origins of radiation therapy. Radiother Oncol. 1997;42(3):213-7. doi: 10.1016/s0167-8140(97)01940-3.
  4. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. 2004;291(3):317-24. doi: 10.1001/jama.291.3.317.
  5. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-37. doi: 10.1093/neuonc/not114.
  6. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-41. doi: 10.1056/NEJMoa013128.
  7. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160-70. doi: 10.1038/nrd1958.
  8. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467-74. doi: 10.1016/S1470-2045(09)70101-9.
  9. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-37. doi: 10.1093/neuonc/not114.
  10. Slade AN, Stanic S. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases. Contemp Clin Trials. 2016;47:74-7. doi: 10.1016/j.cct.2015.12.013.
  11. Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol. 2014;15(4):539-50. doi: 10.1007/s11864-014-0307-3.
  12. Seyedan M, Fallah M. Validity and reliability of the Persian version of Mini-Mental Status Examination   [In Persian]  Journal of Medical Council of Iran. 2007;25(4):408-14,
  13. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922-35. doi: 10.1111/j.1532-5415.1992.tb01992.x.
  14. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci. 2013;33(23):9626-34. doi: 10.1523/JNEUROSCI.0482-13.2013.
  15. Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715-23. doi: 10.1177/1352458510367662.
  16. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. 2007;21(14):1877-86. doi: 10.1097/QAD.0b013e32813384e8.
  17. Dohopolski M, Hannan R, Wardak Z, Hammers H, Garant A. The reintroduction of radiotherapy into the integrated management of kidney cancer. Cancer J. 2020 Sep/Oct;26(5):448-459. doi: 10.1097/PPO.0000000000000475.
  18. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-37. doi: 10.1093/neuonc/not114.